
Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen
Keywords: Myeloma; Immunohistochemistry; Cyclin D1; FGFR3; p53; Cyclin D3; Thalidomide